Among the Th17 cytokines, IL-17 and IL-22 had strong effect for the induction of H4R and RANKL expression and the differentiation into osteoclasts among three cytokines, so IL-22 or IL-17/H4R axis could be potential therapeutic target for RA-associated bone destruction. This evidence concerns the gene IL22 and rheumatoid arthritis.